|
Emtricitabine
resources
|
|
|
|
|
|
DRUG INFO
Emtricitabine
Drug Name:
Emtricitabine
Indication: For the treatment of HIV-1 infection in adults.
Pharmacology: Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Emtricitabine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.
Mechanism Of Action: Emtricitabine, a synthetic nucleoside analogue of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine substrate deoxycytidine 5'-triphosphate and by incorporating into nascent viral DNA, which results in chain termination. Emtricitabine 5'-triphosphate is a weak inhibitor of mammalian DNA polymerases alpha, beta, and epsilon and of mitochondrial DNA polymerase gamma. Emtricitabine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA.
Drug Category: Anti-HIV Agents; ATC:J05AF09
Brand Names/Synonyms: 524W91; BW 1592; BW 524W91; Coviracil; DRG-0208; Dotfc; Emtricitabine; Emtriva; FTC; Racivir; Truvada
Dosage Forms: TABLETS
Absorption: Rapidly absorbed (93%)
Interactions:
DrugBank: Interactions for Emtricitabine
Interactions for Emtricitabine:
The potential for drug interactions with EMTRIVA has been studied in combination with indinavir,
stavudine, famciclovir, and tenofovir disoproxil fumarate. There were no clinically significant drug interactions for
any of these drugs.
Chemical IUPAC Name: 4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-pyrimidin-2-one
Chemical Formula: C8H10FN3O3S
Half Life: 10 hours
Drug Type: Approved Drug
# Accession No: APRD00226
CAS Registry Number: 143491-57-0
|
|
|
|
|
|
Emtricitabine News
(When available)
Zoek in het archief Jan 9, 2006
Netherlands Corporate News (persbericht), About Truvada Truvada combines Emtriva(R) (emtricitabine) and Viread(R) (tenofovir disoproxil fumarate) in one tablet taken once a day in combination with ...
Companies Anticipate Filing New Drug Application in Second Quarter ... Jan 9, 2006
Nieuwsbank (persbericht), Truvada combines Emtriva® (emtricitabine) and Viread® (tenofovir disoproxil fumarate) in one tablet taken once a day in combination with other antiretroviral ...
Bristol-Myers Squibb and Gilead Announce Data Supporting ... Jan 9, 2006
Finanzen.net, Truvada combines Emtriva(R) (emtricitabine) and Viread(R)(tenofovir disoproxil fumarate) in one tablet taken once a day incombination with other antiretroviral ...
Gilead, Bristol Won't Quit on HIV Drug Jan 9, 2006
TheStreet.com The combination pill contains Sustiva from Bristol-Myers and Truvada from Gilead. Truvada is a once-a-day combination of Emtriva and Viread from Gilead. ...
Gilead Says HIV Pill May Be Available in '06 Jan 10, 2006
Los Angeles Times, Researchers showed that a single pill combining Gilead's Viread and Emtriva medicines and Bristol-Myers' Sustiva was equivalent to taking the three drugs ...
Companies announce success in forming single-pill anti-HIV regimen Jan 9, 2006
The Advocate, Truvada into a single formulation. Truvada is already a combination pill containing Emtriva and Viread. The companies plan to file ...
3 Companies, Emory to Get 2006 GBP Deal of Year Honors Dec 20, 2005
PharmaLive.com (press release), Emory University received $525 million from Gilead Sciences and Royalty Pharma for monetizing its royalty stream from sales of Emtriva. ...
Georgia Biomedical Partnership announces deal of the year awards Dec 20, 2005
Atlanta Business Chronicle, Sciences Inc. and Royalty Pharma Inc., for discovering the drug Emtriva, which treats HIV-1, the virus which causes AIDS. Cardiomems ...
ICAAC: Switching from Combivir to Truvada has benefits for ... Jan 11, 2006
Aidsmap, ...the chances of a patient achieving a viral load below 50 copies/ml, according to a study involving Gilead Sciences, the manufacturers of Truvada which was ...
Gilead and BMS to seek regulatory approval for efavirenz, Truvada ... Jan 10, 2006
Aidsmap, ...and Bristol Myers Squibb (BMS) announced that they now have data showing that a fixed dose combination pill combining Gilead’s Truvada (tenofovir and FTC ...
Gilead's Truvada Seen Driving Switchers From Combivir Dec 19, 2005
Forbes ...rating and $70 price target on Gilead Sciences (nasdaq: GILD - news - people ) after data from the COMET (Combination of Efavirenz and Truvada) trial presented ...
Zoek in het archief Jan 9, 2006
Netherlands Corporate News (persbericht), BMY) Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva and Truvada Pharmaceutical Writers ...
Bristol-Myers Squibb and Gilead Announce Data Supporting ... Jan 9, 2006
Business Wire (press release), ...bioequivalence of a new formulation of the fixed-dose combination of Bristol-Myers Squibb's Sustiva(R) (efavirenz) and Gilead's Truvada(R) (emtricitabine and ...
Bristol-Myers Squibb and Gilead Announce Data Supporting ... Jan 9, 2006
Finanzen.net, ...of a new formulation of the fixed-dose combination ofBristol-Myers Squibb's Sustiva(R) (efavirenz) and Gilead's Truvada(R)(emtricitabine and tenofovir ...
Companies announce success in forming single-pill anti-HIV regimen Jan 9, 2006
The Advocate, The companies on Monday announced they’ve successfully combined the drugs Sustiva and Truvada into a single formulation. Truvada ...
Gilead, Bristol Won't Quit on HIV Drug Jan 9, 2006
TheStreet.com The combination pill contains Sustiva from Bristol-Myers and Truvada from Gilead. Truvada is a once-a-day combination of Emtriva and Viread from Gilead. ...
Bristol-Meyers Squibb, Gilead advance single-dose HIV drug Jan 12, 2006
Dallas Voice, The new combination drug will combine Bristol-Meyers’ Sustiva with Gilead’s Truvada in a one-pill fixed dose, using a process called “bi-layer ...
Merck, Gilead in integrase-inhibitor race Jan 13, 2006
Science Daily (press release) ...analyst Ron Ellis rated Gilead "underweight" this week based partly on the company's announcement that its triple HIV co-formulation of Truvada and Bristol ...
Brisol-Myers, Gilead advance combo AIDS treatment Jan 9, 2006
Reuters The companies said the new data supports bioequivalence of Bristol's Sustiva and Gilead's Truvada, which make a new combination treatment for HIV infection in ...
|
|
|
